CAPTRUST Financial Advisors
ENTA icon

CAPTRUST Financial Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-870
Closed -$41K – 2641
2022
Q2 		$41K Buy
870
+18
+2% +$977 ﹤0.01% 2904
2022
Q1 		$61K Buy
852
+660
+344% +$42.9K ﹤0.01% 2644
2021
Q4 		$14K Buy
192
+10
+5% +$785 ﹤0.01% 3514
2021
Q3 		$10K Sell
182
-1
-0.5% -$49 ﹤0.01% 3598
2021
Q2 		$8K Sell
183
-48
-21% -$2.35K ﹤0.01% 3658
2021
Q1 		$11K Buy
231
+191
+478% +$9.53K ﹤0.01% 3381
2020
Q4 		$2K Buy
40
+20
+100% +$880 ﹤0.01% 3099
2020
Q3 		$1K Buy
+20
New +$969 ﹤0.01% 2888

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

CAPTRUST Financial Advisors's ENTA Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2022, closing a stake of 870 shares — an estimated $41K sold.

CAPTRUST Financial Advisors first reported a position in ENTA in Q3 2020 and held it in 8 quarters. The position peaked at $61K in Q1 2022. 159 funds tracked by Wall St. Rank hold ENTA as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 870 Enanta Pharmaceuticals shares in Q3 2022, an estimated $41K.
  • CAPTRUST Financial Advisors first reported a position in Enanta Pharmaceuticals in Q3 2020 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's Enanta Pharmaceuticals position peaked at $61K in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.